ELDN

Eledon Pharmaceuticals, Inc. ELDN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$184.75M total
BVF INC/IL
$24.80M0.0%
BlackRock, Inc.
$20.19M+16.9%
Defilade Capital Management, L.P.
$13.89M-1.1%
VANGUARD CAPITAL MANAGEMENT LLC
$13.46M+3.8%
GOLDMAN SACHS GROUP INC
$9.89M+578.3%
Ensign Peak Advisors, Inc
$8.28M-14.8%
GEODE CAPITAL MANAGEMENT, LLC
$7.71M+9.2%
Catalio Capital Management, LP
$6.68M+3.4%
STATE STREET CORP
$6.39M+40.5%
Zimmer Partners, LP
$6.29M-14.8%
SPHERA FUNDS MANAGEMENT LTD.
$4.69M-32.8%
AWM Investment Company, Inc.
$4.33M0.0%
UBS Group AG
$4.13M+91.5%
KINGDON CAPITAL MANAGEMENT, L.L.C.
$4.09M0.0%
MILLENNIUM MANAGEMENT LLC
$3.86MNew
BANK OF AMERICA CORP /DE/
$3.48M+1.6%
ADAR1 Capital Management, LLC
$2.55M-33.5%
22NW, LP
$2.51M0.0%
NORTHERN TRUST CORP
$2.43M+13.3%
AQR CAPITAL MANAGEMENT LLC
$2.29M+237.0%
CM Management, LLC
$2.27M-11.5%
Blue Owl Capital Holdings LP
$2.23M-60.1%
DIMENSIONAL FUND ADVISORS LP
$2.12M+703.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.10M+24.1%
VANGUARD FIDUCIARY TRUST CO
$2.08M+5.0%
See all 162 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ELDN

Earnings Per Share

13fpro.ai/company/ELDN

Loading ratio trend…

ELDN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Eledon Pharmaceuticals, Inc. (ELDN): stock profile, AI score and financials

Eledon Pharmaceuticals, Inc. (ELDN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ELDN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ELDN by reported 13-F value include BVF, BlackRock, Defilade Capital Management, L.P., based on the most recent SEC filings. ELDN trades on the Nasdaq exchange and files with the SEC under CIK 1404281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eledon Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1404281 →